GM-CSF can be targeted for the treatment of RA because it is abundant in RA synovium in association with strong activation of synovial macrophages, and active production of IL-6 and TNFα in RA joints (28, 29). This evidence concerns the gene CSF2 and rheumatoid arthritis.